Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
Yuzhen Qian, Yixuan Sun, Peishang Shi, Xiuman Zhou, Qiongqiong Zhang, Qingyu Dong, Shengzhe Jin, Lu Qiu, Xiaoshuang Niu, Xiaowen Zhou, Wenshan Zhao, Yahong Wu, Wenjie Zhai, Yanfeng Gao
Abstract
Aside from antibodies, peptides show great potential as immune checkpoint inhibitors (ICIs) due to several advantages, such as better tumor penetration and lower cost. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint which can induce T cell dysfunction through interaction with its soluble ligand fibrinogen like protein-1 (FGL1). Here, we found that LAG-3 expression was higher than programmed cell death protein 1 (PD-1) in multiple human cancers by TCGA databases, and successfully identified a LAG-3 binding peptide LFP-6 by phage display bio-panning, which specifically blocks the interaction of LAG-3/FGL1 but not LAG-3/MHC-II. Subsequently, d -amino acids were introduced to substitute the N- and C-terminus of LFP-6 to obtain the proteolysis-resistant peptide LFP-D1, which restores T cell function in vitro and inhibits tumor growth in vivo . Further, a bispecific peptide LFOP targeting both PD-1/PD-L1 and LAG-3/FGL1 was designed by conjugating LFP-D1 with PD-1/PD-L1 blocking peptide OPBP-1(8–12), which activates T cell with enhanced proliferation and IFN- γ production. More importantly, LFOP combined with radiotherapy significantly improve the T cell infiltration in tumor and elevate systemic antitumor immune response. In conclusion, we developed a novel peptide blocking LAG-3/FGL1 which can restore T cell function, and the bispecific peptide synergizes with radiotherapy to further enhance the antitumor immune response. The LFP-D1 peptide specifically blocks the interaction between LAG-3 and FGL1, and LFOP peptide provides a biological rationale for co-blockade LAG-3/FGL1 and PD-1/PD-L1 pathway as an effective cancer immunotherapeutic strategy when combined with radiotherapy.